Craig-Hallum raised its price target for Exact Sciences to $127 from $115 following “exceptional” Q2 results.
Exact Sciences (EXAS) delivered a major preannounced Q2 beat and raise as well as a $2.8B buyout offer for Genomic Health (GHDX).
Prices have been consolidating lately. There is a very little resistance above the current price. There is a support zone below the current price at $116.99, a stop order could be placed below this zone.
Exact Sciences does not meet the requirements for an addition to the GST Portfolio but a short-term swing trade may be available, just keep a tight stop on it if you go for it.
Disclosure: I have no position in EXAS.